|Description||EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EPZ-6438 induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells. Treatment of xenograft-bearing mice with EPZ-6438 leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and portend the utility of EZH2-targeted drugs for the treatment of these genetically defined cancers. EPZ-6438 is currently in clinical trials.|
|B0084-462339||1 g||$498||In stock|
|Appearance||white solid powder|
|Synonyms||EPZ-6438; EPZ 6438; EPZ6438.|
|Current Developer||Epizyme, Inc., Cambridge, MA 02139.|
UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wildtype and mutant EZH2 as well as EZH1. UNC1999 was highly selective for E...
EPZ005687 is a selective EZH2 enzyme inhibitor with Ki of 24 nM. It is 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyl...
UNC 2400 is a negative control of UNC 1999 that displays 1000-fold lower potency than active analog (IC50 = 62 and >200 μM for EZH1 and EZH2, respectively).
GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity. GSK126 decreases global H3...
PF 06726304 is a selective inhibitor of Histone-lysine N-methyltransferase EZH2 (enhancer of Zeste homolog 2) (IC50 = 0.7 nM). It inhibits proliferation of Karp...
GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different can...
CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase that targets the degradation of EZH2.